Publication | Open Access

First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial

Checkmate 743MedicinePathologyPleural DiseaseCancer TreatmentOncologyRadiation Oncology